Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.
Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.
复制标题
通过时间灭活测定评估奥利万星与利福平、庆大霉素或利奈唑胺的组合对假体关节感染相关的耐甲氧西林金黄色葡萄球菌生物膜的影响。
DOI：
10.1128/aac.00943-18
复制
发表时间：
2018
影响因子：
4.9
通讯作者：
Patel,Robin
中科院分区：
文献类型：
--
作者：
Yan,Qun;Karau,MelissaJ;Raval,YashS;Patel,Robin
通过时间杀灭试验，评价了奥利万星联合利福平、庆大霉素或利奈唑胺对10株人工关节感染（PJI）相关耐甲氧西林金黄色葡萄球菌（MRSA）分离株的抗菌膜活性。对于所有10株分离株，与任一种抗菌剂单独给药相比，奥利万星联合利福平显示出统计学显著性细菌减少（P≤ 0.001），在80%的分离株中观察到协同作用。奥利万星和利福平联合治疗可能是治疗MRSA PJI的一种选择。
The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)-related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.